Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study

Size: px
Start display at page:

Download "Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study"

Transcription

1 Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study Mahyar Etminan, 1,2, * Sean C. Skeldon, 3,4 Sheldon Larry Goldenberg, 3 Bruce Carleton, 1,2 and James M. Brophy 5 1 Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; 2 Therapeutic Evaluation Unit, Child & Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada; 3 Department of Urological Science, University of British Columbia, Vancouver, British Columbia, Canada; 4 Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada; 5 Department of Medicine, McGill University, Montreal, Quebec, Canada BACKGROUND Recent studies have provided conflicting and controversial results about the risk of cardiovascular events, including myocardial infarction (MI), with testosterone replacement therapy (TRT). The potential adverse effects of different TRT formulations and duration of therapy on MI risk are unknown. METHODS We performed a case-control study within a cohort of 934,283 men aged from the IMS LifeLink Health Plan Claims Database. For each case of MI, four controls were identified using density-based sampling. Rate ratios (RRs) were computed for current and past TRT users. As a sensitivity analysis, the risk of MI before and after the start of a first-time TRT prescription in the same patient was also computed. RESULTS We identified 30,066 MI cases and 120,264 corresponding controls. Current use of TRT was not associated with an increased risk of MI (RR 1.01, 95% confidence interval [CI] ); first-time users did show an increased risk (RR 1.41, 95% CI ; number needed to harm 305). There was no association between MI and past TRT users and no differences among the different formulations. The RRs for current use and first-time use of TRT in men with a previous history of coronary artery disease were 1.05 (95% CI ) and 1.78 (95% CI ), respectively. CONCLUSION In this large observational study, an association between MI and past or current TRT use was not found. However, a statistically significant association was observed between first-time TRT exposure and MI, although the absolute risk was low. KEY WORDS testosterone therapies, myocardial infarction, case-control study, drug safety. (Pharmacotherapy 2015;35(1):72 78) doi: /phar.1534 Testosterone replacement therapy (TRT) has grown increasingly popular over the past decade. From 2001 to 2011, prescriptions for men *Address for correspondence: Mahyar Etminan, Therapeutic Evaluation Unit, Child & Family Research Institute of British Columbia, Faculty of Medicine, University of British Columbia, A4-198 WS 2, West 28th Avenue, Vancouver, BC, Canada; metminan@popi.ubc. ca, metminan@shaw.ca. Ó 2015 Pharmacotherapy Publications, Inc. aged 40 years or older have tripled, 1 with sales in the United States reaching $1.6 billion in Part of this growth is attributed to the popularity and direct-to-consumer marketing of new testosterone formulations such as topical gels and solutions. 3 5 Moreover, recent evidence suggests that another component of the growth may be expanded and/or inappropriate prescribing, especially in the United States and United Kingdom. 1, 6 For example, among men newly prescribed TRT in the United Kingdom, 54% did

2 TESTOSTERONE THERAPIES AND MYOCARDIAL INFARCTION RISK Etminan et al 73 not have their testosterone level measured in the preceding 180 days. 7 A large body of literature suggests an association between low testosterone levels in men and increased risk of cardiovascular adverse events and mortality Although TRT in hypogonadal men would therefore appear to be rational, 14 it remains unproved and highly controversial. In 2009, a small randomized trial 15 designed to evaluate the effect of TRT on frailty in older men was terminated early because of a higher number of cardiovascular-related adverse events in the testosterone arm compared with placebo. A meta-analysis of 27 randomized placebo-controlled trials over 12 weeks in length found an increased risk of cardiovascular-related events with testosterone therapy. 16 Conversely, a widely quoted study 14 of 1031 male veterans with low total testosterone ( 250 ng/dl) found that TRT was associated with a decreased risk of death. In the past few years, more conflicting studies have been published, including two large database studies suggesting that TRT use was associated with increased cardiovascular risks. 17, 18 Unfortunately, concerns about methods used in these studies remain and have not been fully addressed. Given the increasing use of TRT, possible inappropriate prescribing with uncertain benefit, and conflicting safety signals, additional studies are clearly required. Therefore, we conducted a large pharmacoepidemiologic study designed to address the cardiovascular risk of TRT, particularly as a function of treatment duration and type of drug formulation. Methods The IMS LifeLink health plan claims database was the main data source. LifeLink 19, 20 data contain physician visits, hospitalizations, procedures, and prescription drug data including dose, quantity of medication dispensed, and number of prescribed days for ~150 million deidentified Americans with fully adjudicated medical claims. The LifeLink data captured a balanced demographic sample from all geographic regions in the United States. LifeLink captured data on 17% of men aged years, 13% of men aged years, and 8% of men older than 65. Data on men older than 65 years were captured through the Medicare Advantage programs. LifeLink did not capture information on Veterans Affairs beneficiaries. LifeLink captured all inpatient and outpatient diagnoses through International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The database was subject to routine quality checks 20 and was used in previous pharmacoepidemiologic studies. Cohort entry started 19, 21 with the first prescription drug, physician visit, or hospitalization from 2001 to Members of the cohort were followed until the occurrence of a study outcome, termination of the insurance claim, or last date of data availability. Men with a previous history of cardiovascular disease were included. We planned a time-matched case-control study, which allowed assessment between time-varying drug exposures and clinical outcomes. This methodology provided similar results as a cohort study using time-dependent Cox regression models. 22 Case and Control Selection The primary outcome was new-onset acute myocardial infarction (MI), defined as a hospitalization occurring after cohort entry with an ICD-9-CM code 410 in the primary or secondary position of the hospital discharge diagnosis. The positive predictive value for this ICD-9 code was between 89% and 97% in similar U.S. administrative claims databases. The date of the 23, 24 first MI was deemed the index date. Data on outpatient deaths were not available, which precluded analysis of total cardiovascular mortality. For each case, a pool of potential controls was identified. To be eligible, controls had to have the same year of birth as the case ( 1 yr), the same calendar year of cohort entry, and the same length of follow-up time. From the eligible pool of controls, four were randomly selected and matched to each case to form a risk set. Each control could have been used more than once for each risk set and could possibly become a future case. This incident density sampling method has been shown to produce incident rate ratios (RRs). 22 Exposure Definitions Testosterone prescriptions were classified by the type of formulation: gels (including solutions), topical patches, injections, or other route of delivery (oral or buccal). Men who filled at least one prescription for TRT within 1 year before the index date were considered testosterone users. The reference nonexposed group was defined as men with no TRT use in the year

3 74 PHARMACOTHERAPY Volume 35, Number 1, 2015 before the index date. Current users were defined as men whose last TRT prescription was within 90 days before the index date (0 90 days); otherwise, testosterone users were classified as past users (91 364). We chose the 90-day risk window because it has been used previously in both observational 18 and randomized studies. 15 Because the risk of adverse drug reactions may be higher for first-time users of drug therapies, 25 we prospectively stratified current users to first-time users (men who received their first TRT prescription in the 90-day window) or prevalent users (men who received a prescription before the 90-day window). This new-user design has been shown to reduce potential survivor and adherence bias in other 26, 27 studies. Statistical Analysis and Covariate Adjustment Causal diagrams were developed to identify true confounding variables and avoid overadjustment bias that may result from adjustment for intermediate variables or colliders (variables that may introduce selection bias). 28 Variables that were risk factors for the outcome, but not for the exposure, were not included in the model. 29 We used conditional logistic regression to adjust for stroke, diabetes, deep vein thrombosis, peripheral vascular disease, chronic renal failure, cancer, and use of statins or antiplatelet drugs. As a quality measure, we also quantified the risk of MI with finasteride, a drug often prescribed for men that has not been shown to be associated with a risk of MI. Finasteride use was defined similar to TRTs. In order to examine the risk of MI in men with a previous history of coronary artery disease, we performed a subgroup analysis in this group by identifying those who had a history of coronary artery disease (ICD-9 codes ) within 1 year before the index date. In order to estimate absolute risk when appropriate, we computed a number needed to harm (NNH) for both the overall and subgroup analyses. All analyses were conducted using SAS version 9.3 (SAS Institute Inc., SAS 9.1. Cary, NC: SAS Institute Inc., ). Sensitivity Analysis Because men with low testosterone levels may inherently have a higher risk of MI, 13 we conducted an additional analysis to control for between-patient confounding. We compared the incident rate of MI among new users of TRT in the 90 days after they filled the first TRT dispensation with the rate of MI in the 90-day period before this dispensation date in the same patient. More specifically, each subject was followed from the date of their first TRT prescription to the first MI or end of the 90-day risk period, whichever came first. Unexposed person time was computed in the same fashion for the 90-day period before the dispensation date. The RRs were computed for exposed and unexposed incident rates using a stratified Cox regression analysis. Thus, this sensitivity analysis eliminates between-patient confounding that may have incurred due to between-subject variability in testosterone levels or other unmeasured confounders. Results We identified 30,066 cases with MI and 120,264 corresponding controls. The mean age for the cases and controls was 70.4 ( 13) years with a mean follow-up of 2.8 ( 2.2) years. Cases were more likely to have been previously diagnosed with stroke, peripheral vascular disease, cancer, or chronic renal failure (Table 1). Among the 515 cases who had used at least one TRT in the year before the index date, testosterone gel was the most common formulation used (n=285), followed by injections (n=133), patch (n=52), and other (n=11). Thirty-four men used more than one type of testosterone product. Current use of TRTs was not associated with an increase in the risk of MI (RR 1.01, 95% CI ) (Table 2). Current first-time users showed a statistically significant association with MI (RR 1.41, 95% CI ), whereas prevalent users did not (RR 0.94, 95% CI ). The RR for past users of any TRT was also not increased (RR 1.04, 95% CI ). In men with a previous history of coronary artery disease, the TRT RRs for any current use and firsttime use were 1.05 (95% CI ) and 1.78 (95% CI ), respectively. Among the different formulations of TRTs, the RRs for first-time users of topical gels was 1.49 (95% CI ) and reached statistical significance as it contributed to greater than 55% of TRT users. Aside from users of testosterone patches, other formulations also showed a consistent pattern of association between MI and firsttime use, although this did not reach statistical significance, possibly due to insufficient power. The NNH for first-time users based on an annual rate of 8 MIs/1000 person-years among

4 TESTOSTERONE THERAPIES AND MYOCARDIAL INFARCTION RISK Etminan et al 75 Table 1. Characteristics of Myocardial Infarction Cases and Their Matched Controls Patient Characteristics Cases (n=30,066) Controls (n=120,264) Age at index date, mean (SD), yr 70.4 (12.9) 70.4 (13.0) Follow-up duration, mean (SD), yr 2.8 (2.2) 2.8 (2.2) Comorbidities the year before index date, % Stroke Diabetes Deep venous thrombosis Peripheral vascular disease Chronic renal failure Cancer Medications the year before index date, % Statins Antiplatelet agents Table 2. Crude and Adjusted Rate Ratios for the Risk of Nonfatal Myocardial Infarction with Use of Testosterone in the Year before the Index Date % Rate Ratio (95% CI) Cases (n=30,066) Controls (n=120,264) Crude Adjusted a No testosterone use b 29, , (Reference) Any testosterone use c ( ) Current use ( ) First-time user ( ) Prevalent user ( ) Past use ( ) Specific formulations Gel or spray ) Current use ( ) First-time user ( ) Prevalent user ( ) Past use ( ) Patch ( ) Current use ( ) First-time user ( ) Prevalent user ( ) Past use ( ) Injection ( ) Current use ( ) First-time user ( ) Prevalent user ( ) Past use ( ) Other d ( ) Current use ( ) First-time user ( ) Prevalent user ( ) Past use ( ) a Adjusted for age, stroke, diabetes, deep venous thrombosis, peripheral vascular disease, chronic renal failure, cancer, statin use, and antiplatelet agent use. b During the year before the index date. c Use of at least 1 prescription at any time before the index date. d Includes oral and buccal formulations. nonusers of TRTs in the entire cohort was 305. The results of the sensitivity analysis where the risk of MI was examined before and after firsttime TRT use showed similar results to the primary case-control analysis with an incident RR of 1.44 (95% CI ). Also, in the finasteride control group, no increase in the risk of MI was seen with first-time users (RR 0.97, 95% CI ). Discussion In this large retrospective observational study of older men, we observed no association

5 76 PHARMACOTHERAPY Volume 35, Number 1, 2015 between risk of MI and all current or past use of TRTs. However, our study did demonstrate a 41% increase in the risk of MI with current firsttime users. These apparently discordant findings between first-time and repeat current users may potentially be explained by a depletion of susceptibles after the initial TRT prescription. Fortunately, in this population, the absolute risk for first-time TRT users was small, resulting in an overall large NNH of 305. Consistent findings were also observed in the population restricted to men with established coronary artery disease, although the increased risk for first-time users in this subcohort did not reach statistical significance, perhaps due to a lack of power due to the smaller sample size (Table 3). 17, 18 Two recent epidemiologic studies suggested an increase in the risk of cardiovascular disease with TRT. In the first study, 17 the risk of a composite end point of all-cause mortality, MI, or ischemic stroke in men with low testosterone (< 300 ng/dl) who underwent coronary angiography after having filled a prescription for TRT was examined. That study found an absolute higher rate of events after 3 years in those not treated with TRT compared with those who were treated (21.2% vs 10.1%). However, after multivariable analysis with stabilized inverse probability weighting, TRT became associated with an increased risk of adverse events (hazard ratio 1.29, 95% CI ). In the second study, a large retrospective U.S. health claims database study that did not report on testosterone levels, 18 the rates of MI among new TRT and phosphodiesterase type 5 inhibitor (PDE5i) users were compared. They reported an RR for TRT compared with PDE5i therapy of 1.90 (95% CI ), with a higher risk among men with a prior history of cardiovascular disease (RR 2.90, 95% CI ). These studies have several limitations. The first study 17 has been challenged due to ambiguous cohort entry criteria and exclusion criteria. 30 In the second study, 18 the use of PDE5i as a control group is perhaps problematic as the cardiovascular risk profile may have been different from that of TRT users, although a within-subject analysis did demonstrate an increase in the risk of MI with TRT (RR 1.36, 95% CI ). However, this study had a short follow-up and contained only a small number of events, so the overall robustness of the results is limited. Finally, both of these studies looked at the risk of TRT in men only after a single prescription and neither examined the risk with different types of TRT formulations. Our study has several strengths. First, due to the large sample size, it includes the largest number of cases of MI with TRT exposure (n=515). Second, our analyses controlled for the most common potential confounders and examined the time dependency of TRT risk patterns. Third, our before and after sensitivity analyses, which effectively removed between-subject variability, provided consistent results. Fourth, the confirmed neutral findings for our control drug, finasteride, provide some additional quality assurance. Fifth, our study had adequate statistical power to potentially show an increase in the risk of MI, if it existed, with gel formulations, the most common formulations of TRTs used in North America. Finally, the observed trend for increased MI risk in first-time users with previous history of cardiovascular disease is in concordance with two previously published 17, 18 epidemiologic studies. As with all pharmacoepidemiologic studies, our study is not without limitations. While our outcome of MI is of sufficient severity that it is probably well measured by a hospitalization, there is Table 3. Crude and Adjusted Rate Ratios for the Risk of Nonfatal Myocardial Infarction with Use of Testosterone Among Subjects with Prior History of Cardiac Events in the Year before the Index Date % Rate Ratio (95% CI) Cases (n=9446) Controls (n=14,638) Crude Adjusted a No testosterone use b , (Reference) Any testosterone use c ( ) Current use ( ) First-time user ( ) Prevalent user ( ) Past use ( ) a Adjusted for age, stroke, diabetes, deep venous thrombosis, peripheral vascular disease, chronic renal failure, cancer, statin use, and antiplatelet agent use. b During the year before the index date. c Use of at least 1 prescription at any time before the index date.

6 TESTOSTERONE THERAPIES AND MYOCARDIAL INFARCTION RISK Etminan et al 77 uncertainty around the exposure measure and the etiologic risk window. To be consistent with previous studies, we defined a 90-day period from the last prescription as being currently exposed, but it is unknown if this represents the true etiologic window. Moreover, we only have information on drug dispensed and not actual exposure status. This may lead to nondifferential exposure misclassification, which may underestimate the true risk with TRT. There is also the possibility that unmeasured confounding may exist. For example, we did not have access to information on ethnicity, socioeconomic status, or lifestyle factors in our data. However, the within-patient sensitivity analysis would have controlled for these confounding variables and provided consistent results with our primary analysis. For both the main analysis and the sensitivity analysis, we did not have mortality data and could not exclude the possibility of an out-of-hospital death. However, such a bias, if present, would underestimate the risk association. Also, we did not have detailed information on the indication or appropriateness of TRT prescriptions, including serum testosterone levels before or during treatment. Therefore, we cannot draw any generalizable conclusions regarding the safety of testosterone therapy in men with properly diagnosed hypogonadism. While not all the results of our study are concordant with the previous studies, they do raise a potential MI safety signal among first-time TRT-exposed men. Given the higher baseline risk in patients with preestablished cardiovascular disease, this safety signal is potentially most concerning in this group. This was a generally consistent finding, regardless of the type of testosterone formulation. Given this potential safety signal and the absence of established benefit for off-label use, TRT should be reserved only for men with clinically symptomatic and biochemically proven hypogonadism as recommended by current guidelines with appropriate monitoring for adverse events. 31 Until further, more definitive studies are completed and published, 32 it would appear prudent, in the spirit of fully informed consent, to advise all new TRT users to weigh the benefits of therapy against a small potential increase in the risk of MI. Conflict of Interest None of the authors have any conflicts of interest to declare. Dr. Brophy receives salary and operating support from the FRQS (Fonds de recherche du Quebec-Sante), a nonprofit provincial funding agency. The funding agency had no influence on the choice of study topic, the analyses, or the conclusions. Dr. Carleton s research is supported by national granting agencies such as the Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation (CFI), Genome British Columbia, and the Child & Family Research Institute. References 1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to JAMA Intern Med 2013;173: Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013;9: Kamerow D. Getting your T up. BMJ 2014;348:g Delamothe T. Monkey business: reflections on testosterone. BMJ 2012;345:e Schwartz LM, Woloshin S. Low, T as in template : how to sell disease. JAMA Intern Med 2013;173: Gan EH, Pattman S, Pearce S, Quinton R. Many men are receiving unnecessary testosterone prescriptions. BMJ 2012;345:e Layton JB, Li D, Meier CR, et al. Testosterone Lab Testing and Initiation in the United Kingdom and the United States, J Clin Endocrinol Metab 2014;99(3): (In Press). 8. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78: Khaw K-T, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116: Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166: Laughlin Ga, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93: Haring R, V olzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged Eur Heart J 2010;31: Ruige JB, Mahmoud AM, De Bacquer D, Kaufman J-M. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011;97: Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97: Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363: Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11: Vigen R, O Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310: Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 2014;9:e85805.

7 78 PHARMACOTHERAPY Volume 35, Number 1, Etminan M, Delaney JAC, Bressler B, Brophy JM. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011;183: LifeLink Health Plan Claims Database: overview and study design issues. [Internet] Available from TRI/hsrcore/Lifelink_Health_Plan_Claims_Data_DesignIssues_wcost_April2010[1].pdf. Accessed 28 February Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JAC. The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clin Pharmacol 2011;11: Essebag V, Genest J, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003;146: Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304: Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med 1999;14: Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158: Ray Wa, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360: Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006;174: Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009;20: Hernan M. Causal Inference Book [Internet]. 2015:96. Available from: Accessed 24 April Morgentaler A, Kacker R. Andrology: Testosterone and cardiovascular risk deciphering the statistics. Nat Rev Urol 2014;11: Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95: Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: seven coordinated trials of testosterone treatment in elderly men. Clin Trials 2014;11(3): (In Press).

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01.

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01. Testosterone Therapy and Mortality Risk Michael L. Eisenberg, MD 1, Shufeng Li, MS 2, Danielle Herder, MD 3, Dolores J. Lamb, PhD 4, and Larry I. Lipshultz, MD 4 1 Assistant Professor, Departments of Urology

More information

Disclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI

Disclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI Testosterone, the FDA and CVD Risk Controversies Faculty Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI 2 Disclosures Matt Rosenberg, MD serves on the advisory board for Bayer,

More information

Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis

Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis CMAJ Research Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis Steven T. Bird PharmD MS, Abraham G. Hartzema PhD PharmD, James M. Brophy

More information

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV

More information

Zhao Y Y et al. Ann Intern Med 2012;156:

Zhao Y Y et al. Ann Intern Med 2012;156: Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled

More information

RESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access

RESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink

More information

Observational Study Designs. Review. Today. Measures of disease occurrence. Cohort Studies

Observational Study Designs. Review. Today. Measures of disease occurrence. Cohort Studies Observational Study Designs Denise Boudreau, PhD Center for Health Studies Group Health Cooperative Today Review cohort studies Case-control studies Design Identifying cases and controls Measuring exposure

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa

More information

Case 3:15-cv PLR-HBG Document Filed 01/20/17 Page 1 of 5 PageID #: 1412

Case 3:15-cv PLR-HBG Document Filed 01/20/17 Page 1 of 5 PageID #: 1412 6 Case 3:15-cv-00137-PLR-HBG Document 33-36 Filed 01/20/17 Page 1 of 5 PageID #: 1412 588084TAW0010.1177/2042098615588084Therapeutic Advances in Drug SafetyEtminan research-article2015 Therapeutic Advances

More information

Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes.

Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes. Wu, J. W., Azoulay, L., Majdan, A., Boivin, J. F., Pollak, M., and Suissa, S. Journal of Clinical

More information

Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults

Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults FINAL Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults April 29 th, 2015 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca

More information

The reality of LOH-symptoms

The reality of LOH-symptoms The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone

More information

CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL?

CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL? CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL? Mette Nørgaard, Professor, MD, PhD Department of Clinical Epidemiology Aarhus Universitety Hospital Aarhus, Denmark Danish Medical Birth Registry

More information

THIS TALK STATINS REDUCE: Immortal time bias Immeasurable time bias Time-window bias TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY

THIS TALK STATINS REDUCE: Immortal time bias Immeasurable time bias Time-window bias TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY Samy Suissa McGill University and Jewish General Hospital Montreal, Canada ISPE mid-year meeting, Miami April 22, 2012 STATINS REDUCE: JAMA 2000: Fracture rate

More information

Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases

Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of

More information

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Generalizing the right question, which is?

Generalizing the right question, which is? Generalizing RCT results to broader populations IOM Workshop Washington, DC, April 25, 2013 Generalizing the right question, which is? Miguel A. Hernán Harvard School of Public Health Observational studies

More information

Erectile Dysfunction, Cardiovascular Risk and

Erectile Dysfunction, Cardiovascular Risk and Erectile Dysfunction, Cardiovascular Risk and Testosterone National Lipid Association (NLA) 2016 Fall Clinical Update August 26-28, 2016 Amelia Island, Fl Robert A. Kloner MD, PhD Director of the Cardiovascular

More information

No Association between Calcium Channel Blocker Use and Confirmed Bleeding Peptic Ulcer Disease

No Association between Calcium Channel Blocker Use and Confirmed Bleeding Peptic Ulcer Disease American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 4 Printed in U.S.A. A BRIEF ORIGINAL CONTRIBUTION No

More information

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency

More information

Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies

Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies September 27, 2018 Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies A Case Study of Screening Colonoscopy Our Team Xabier Garcia

More information

The University of Mississippi School of Pharmacy

The University of Mississippi School of Pharmacy LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.

More information

Friday and weekend hospital stays: effects on mortality

Friday and weekend hospital stays: effects on mortality ERJ Express. Published on May 14, 2014 as doi: 10.1183/09031936.00007714 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Friday and weekend hospital stays: effects on mortality Samy Suissa 1,2, Sophie Dell Aniello

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

RESEARCH. Susan S Jick, director and senior epidemiologist Rohini K Hernandez, epidemiologist

RESEARCH. Susan S Jick, director and senior epidemiologist Rohini K Hernandez, epidemiologist Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY

More information

Testosterone therapy in the new era of Food and Drug Administration oversight

Testosterone therapy in the new era of Food and Drug Administration oversight Review Article Testosterone therapy in the new era of Food and Drug Administration oversight Bethany Desroches 1, Taylor P. Kohn 2, Charles Welliver 3, Alexander W. Pastuszak 1,4 1 Scott Department of

More information

Mina Tadrous, Diana Martins, Zhan Yao, Kimberly Fernandes, Samantha Singh, Nikita Arora, David Juurlink, Muhammad Mamdani and Tara Gomes

Mina Tadrous, Diana Martins, Zhan Yao, Kimberly Fernandes, Samantha Singh, Nikita Arora, David Juurlink, Muhammad Mamdani and Tara Gomes Cognitive Enhancers Pharmacoepidemiology Report: FINAL CENSORED Report Mina Tadrous, Diana Martins, Zhan Yao, Kimberly Fernandes, Samantha Singh, Nikita Arora, David Juurlink, Muhammad Mamdani and Tara

More information

Supplementary Text A. Full search strategy for each of the searched databases

Supplementary Text A. Full search strategy for each of the searched databases Supplementary Text A. Full search strategy for each of the searched databases MEDLINE: ( diabetes mellitus, type 2 [MeSH Terms] OR type 2 diabetes mellitus [All Fields]) AND ( hypoglycemia [MeSH Terms]

More information

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223

More information

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 CARDIOVASCULAR DISEASE is the leading cause of death in Australia, causing more than 40% of all deaths in 1998. 1 Cardiac rehabilitation

More information

Study Exposures, Outcomes:

Study Exposures, Outcomes: GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic

More information

Leah M Smith, Jay S Kaufman, Erin C Strumpf, Linda E Lévesque

Leah M Smith, Jay S Kaufman, Erin C Strumpf, Linda E Lévesque The effect of HPV vaccination on clinical indicators of sexual behaviour in a population-based cohort of adolescent girls: The Ontario Grade 8 HPV Vaccine Cohort Study Leah M Smith, Jay S Kaufman, Erin

More information

An increasing number of reports are linking infections to

An increasing number of reports are linking infections to Research Reports Antibiotics in Primary Prevention of Stroke in the Elderly Paul Brassard, MD, MSc; Chantal Bourgault, PhD; James Brophy, MD, PhD; Abbas Kezouh, PhD; Samy Suissa, PhD Background and Purpose

More information

Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare

Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare New data A paper published in May 2012 in the British Medical Journal

More information

Finland and Sweden and UK GP-HOSP datasets

Finland and Sweden and UK GP-HOSP datasets Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry

More information

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM S.P. Lee 1 ; K. Lang 2 ; J. Jackel 2 ;

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Pincus D, Ravi B, Wasserstein D. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA. doi: 10.1001/jama.2017.17606 eappendix

More information

CNODES: A Canadian Initiative

CNODES: A Canadian Initiative CNODES: A Canadian Initiative Samy Suissa Lady Davis Institute, Jewish General Hospital McGill University Montreal, Canada PROTECT Conference, EMA, London, 19 February, 2015 PROVINCE OF QUEBEC, CANADA

More information

Online Supplementary Material

Online Supplementary Material Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control

More information

Testosterone and PDE5 inhibitors in the aging male

Testosterone and PDE5 inhibitors in the aging male Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005

More information

Presenter Disclosure Information

Presenter Disclosure Information Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES

More information

Can men on AS be treated with testosterone?

Can men on AS be treated with testosterone? Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering

More information

Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,

Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.

More information

Rates and patterns of participation in cardiac rehabilitation in Victoria

Rates and patterns of participation in cardiac rehabilitation in Victoria Rates and patterns of participation in cardiac rehabilitation in Victoria Vijaya Sundararajan, MD, MPH, Stephen Begg, MS, Michael Ackland, MBBS, MPH, FAPHM, Ric Marshall, PhD Victorian Department of Human

More information

State of the art pharmacoepidemiological study designs for post-approval risk assessment

State of the art pharmacoepidemiological study designs for post-approval risk assessment State of the art pharmacoepidemiological study designs for post-approval risk assessment Cardiac Safety Research Consortium Think Tank Round Table Meeting Thursday, March 6, 2014 Jennifer L. Lund, PhD

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive

More information

HORMONE REPLACEMENT THERAPY

HORMONE REPLACEMENT THERAPY TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors

More information

Complications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화

Complications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화 Complications of Proton Pump Inhibitor Therapy Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화 Background Proton pump inhibitors (PPIs) are among the most commonly prescribed medicines for gastroesophageal

More information

RESEARCH. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

RESEARCH. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database Julia Hippisley-Cox, professor of clinical epidemiology and general practice,

More information

INDIVIDUALIZED MEDICINE

INDIVIDUALIZED MEDICINE CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic

More information

CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS. Mugdha Gokhale.

CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS. Mugdha Gokhale. CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS Mugdha Gokhale A dissertation submitted to the faculty at the University of North Carolina

More information

Primary Care Updates ACP conference 2015

Primary Care Updates ACP conference 2015 Primary Care Updates ACP conference 2015 Richard Rose, MD FACP Assistant Professor University of Utah Department of General Internal Medicine VAMC - Internal Medicine Nothing to disclose Conflicts of interest

More information

Testosterone Therapy in Men An update

Testosterone Therapy in Men An update Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None

More information

LAMA Products for the Treatment of COPD

LAMA Products for the Treatment of COPD FINAL REPORT LAMA Products for the Treatment of COPD Pharmacoepidemiology Unit: Censored Final Report Tara Gomes, Andrea Gershon, Matthew Stanbrook, Ximena Camacho, Diana Martins, Samantha Singh, Zhan

More information

Bias and confounding special issues. Outline for evaluation of bias

Bias and confounding special issues. Outline for evaluation of bias EPIDEMIOLOGI BIAS special issues and discussion of paper April 2009 Søren Friis Institut for Epidemiologisk Kræftforskning Kræftens Bekæmpelse AGENDA Bias and confounding special issues Confounding by

More information

Identifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada Gomes, T.

Identifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada Gomes, T. UvA-DARE (Digital Academic Repository) Identifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada Gomes, T. Link to publication Citation for published version

More information

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission; Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries Weiss J P, Saynina O, McDonald K M, McClellan M

More information

The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP

The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,

More information

FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES

FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES http://www.lef.org/ FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES By Blake Gossard, Kira Schmid, ND, Luke Huber, ND, MBA, Steven V. Joyal, MD The precipitous decline of men's testosterone

More information

Low T? Late Onset Hypogonadism

Low T? Late Onset Hypogonadism University of Vermont ScholarWorks @ UVM Family Medicine Clerkship Student Projects College of Medicine 2014 Low T? Late Onset Hypogonadism Cheng-Wei Huang University of Vermont Follow this and additional

More information

Using negative control outcomes to identify biased study design: A self-controlled case series example. James Weaver 1,2.

Using negative control outcomes to identify biased study design: A self-controlled case series example. James Weaver 1,2. Using negative control outcomes to identify biased study design: A self-controlled case series example James Weaver 1,2 1Janssen Research & Development, LLC, Raritan, NJ, USA 2 Observational Health Data

More information

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox

More information

Ann Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161

Ann Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161 Ann Rheum Dis 2017;76:1642 1647. doi:10.1136/annrheumdis-2016-211066 Lin, Wan-Ting 2018/05/161 Introduction We and others have previously demonstrated an increased risk of acute coronary syndrome (ACS)

More information

Handling time varying confounding in observational research

Handling time varying confounding in observational research Handling time varying confounding in observational research Mohammad Ali Mansournia, 1 Mahyar Etminan, 2 Goodarz Danaei, 3 Jay S Kaufman, 4 Gary Collins 5 1 Department of Epidemiology and Biostatistics,

More information

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice 10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia

More information

Role of Pharmacoepidemiology in Drug Evaluation

Role of Pharmacoepidemiology in Drug Evaluation Role of Pharmacoepidemiology in Drug Evaluation Martin Wong MD, MPH School of Public Health and Primary Care Faculty of Medicine Chinese University of Hog Kong Outline of Content Introduction: what is

More information

Jacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301

Jacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301 Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

Statins and newly diagnosed diabetes

Statins and newly diagnosed diabetes DOI:10.1111/j.1365-2125.2004.02142.x British Journal of Clinical Pharmacology Statins and newly diagnosed diabetes Susan S. Jick & Brian D. Bradbury Boston Collaborative Drug Surveillance Program, 11 Muzzey

More information

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca

More information

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

More information

Leflunomide Use and the Risk of Interstitial Lung Disease in Rheumatoid Arthritis

Leflunomide Use and the Risk of Interstitial Lung Disease in Rheumatoid Arthritis ARTHRITIS & RHEUMATISM Vol. 54, No. 5, May 2006, pp 1435 1439 DOI 10.1002/art.21806 2006, American College of Rheumatology Leflunomide Use and the Risk of Interstitial Lung Disease in Rheumatoid Arthritis

More information

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of

More information

American Journal of Internal Medicine

American Journal of Internal Medicine American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced

More information

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Svanström H, Pasternak B, Hviid A. Use of azithromycin and

More information

Guidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct

Guidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42 Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac

More information

Challenges in design and analysis of large register-based epidemiological studies

Challenges in design and analysis of large register-based epidemiological studies FMS/DSBS autumn meeting 2014 Challenges in design and analysis of large register-based epidemiological studies Caroline Weibull & Anna Johansson Department of Medical Epidemiology and Biostatistics (MEB)

More information

DIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA

DIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA DIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA Fran Cunningham, Pharm.D. Department of Veterans Affairs* University of Illinois at Chicago Bruce Lambert, Ph.D. University of

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

Design: This was a retrospective incident user cohort.

Design: This was a retrospective incident user cohort. ORIGINAL ARTICLE Endocrine Care Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000 to 2011 J. Bradley Layton, Dongmei Li, Christoph R. Meier, Julie L. Sharpless,

More information

SESSION 5 2:20 3:35 pm

SESSION 5 2:20 3:35 pm SESSION 2:2 3:3 pm Strategies to Reduce Cardiac Risk for Noncardiac Surgery SPEAKER Lee A. Fleisher, MD Presenter Disclosure Information The following relationships exist related to this presentation:

More information

The New England Journal of Medicine LOW-DOSE INHALED CORTICOSTEROIDS AND THE PREVENTION OF DEATH FROM ASTHMA

The New England Journal of Medicine LOW-DOSE INHALED CORTICOSTEROIDS AND THE PREVENTION OF DEATH FROM ASTHMA LOW-DOSE INHALED CORTICOSTEROIDS AND THE PREVENTION OF DEATH FROM ASTHMA SAMY SUISSA, PH.D., PIERRE ERNST, M.D., SERGE BENAYOUN, M.SC., MARC BALTZAN, M.D., AND BING CAI, M.SC. ABSTRACT Background Although

More information

The Effect of Statin Therapy on Risk of Intracranial Hemorrhage

The Effect of Statin Therapy on Risk of Intracranial Hemorrhage The Effect of Statin Therapy on Risk of Intracranial Hemorrhage JENNIFER HANIFY, PHARM.D. PGY2 CRITICAL CARE RESIDENT UF HEALTH JACKSONVILLE JANUARY 23 RD 2016 Objectives Review benefits of statin therapy

More information

Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA

Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy

More information

Testosterone Replacement Therapy and Cardiovascular Risk: A Review

Testosterone Replacement Therapy and Cardiovascular Risk: A Review pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 130-142 http://dx.doi.org/10.5534/wjmh.2015.33.3.130 Review Article Testosterone Replacement Therapy and Cardiovascular Risk:

More information

Observations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA

Observations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA Observations on US CVD Prevention Guidelines Donald M. Lloyd-Jones, MD ScM FACC FAHA What are Guidelines? Evidence Base for Guidelines Tricoci, JAMA 2009 Evidence Base for Guidelines Tricoci, JAMA 2009

More information

Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels

Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels Research Original Investigation Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels Rebecca Vigen, MD, MSCS; Colin I. O Donnell, MS;

More information

The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UK-based general practice research database

The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UK-based general practice research database British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2012.04326.x The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UK-based general practice

More information

Hepatitis C (HCV) Digestive Health Recognition Program

Hepatitis C (HCV) Digestive Health Recognition Program PQRS #84 Hepatitis C: Ribonucleic Acid (RNA) Effective Clinical Process NQF 0395 Testing Before Initiating Treatment Care Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis

More information

Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*

Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1* Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in

More information

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review British Journal of Clinical Pharmacology DOI:10.1111/bcp.12339 Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review Mary A. De Vera, 1,2 Vidula Bhole, 2 Lindsay

More information

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP OBSERVATIONAL Patient-centered observational analytics: New directions toward studying the effects of medical products Patrick Ryan on behalf of OMOP Research Team May 22, 2012 Observational Medical Outcomes

More information

Title: Use of Beta-blockers and Mortality Following Ovarian Cancer Diagnosis: A Population-Based Cohort Study

Title: Use of Beta-blockers and Mortality Following Ovarian Cancer Diagnosis: A Population-Based Cohort Study Author's response to reviews Title: Use of Beta-blockers and Mortality Following Ovarian Cancer Diagnosis: A Population-Based Cohort Study Authors: Sigrun A Johannesdottir (saj@dce.au.dk) Morten Schmidt

More information

AHA Clinical Science Special Report: November 10, 2015

AHA Clinical Science Special Report: November 10, 2015 www.canheart.ca High-density lipoprotein cholesterol and cause-specific mortality: A population-based study of more than 630,000 individuals without prior cardiovascular conditions Dennis T. Ko, MD, MSc;

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

Epidemiologic study designs

Epidemiologic study designs Epidemiologic study designs and critical appraisal of scientific papers Rolf H.H. Groenwold, MD, PhD Bio sketch MD, PhD in epidemiology Associate professor of Epidemiology at UMC Utrecht Research focus

More information